AntiCancerBody™
BioMedicure is developing AntiCancerBody™ products according to its proprietary immunotherapy platform where the whole cell "giant liposome" cancer vaccine products are used for vaccination. After vaccination,
cancer-cell-specific-polyclonal-antibodies are produced to kill cancer cells specifically.
When the Immunotherapy is combined with biochemotherapy and CancerVaccine™ vaccination, significant progress towards a cancer cure can be made.
Since BioMedicure's AntiCancerBody™ products are derived from CancerVaccine™ induced immune response components, these products are
also cancer type specific and species specific. Learning more about the property of CancerVaccine™ will help in understanding AntiCancerBody™.
CancerVaccine™ are harmless whole-cell "giant liposomes" that induce acquired immune responses against cancer
cells specifically. BioMedicure's breakthroughs are:
- Use of Tumorase™ to treat "solid tumors" grown from enriched cancer stem cells to make whole cell cancer vaccine
- Make the immune system, including macrophages and dendritic cells, view CancerVaccine™ whole cell giant liposomes, as foreign
- Maximize the immune system's ability to digest antigens from each and every giant liposome
- Enhance the immune system for antigen presentation processes
- Allow the immune system to get rid of self-fragments to avoid auto-immune responses
- Make the immune system remember the cancer-cell-specific-antigens
- Make the immune system produce cancer-cell-specific polyclonal antibodies, AntiCancerBody™
- Isolate and purify AntiCancerBody™ products
AntiCancerBody™ products are currently under development. These products will be used to treat metastatic cancer individuals with impaired immune system.
AntiCancerBody™ may kill metastatic cancer cells within hours.
If you have questions about availability of AntiCancerBody™ products or the immunotherapy platform, please email: acb@biomedicure.com
|